The effect of plasma protein binding on in vivo efficacy:

Nature Reviews Drug Discovery 9, 929-939 DOI: 10.1038/nrd3287

Citation Report

#	Article	IF	CITATIONS
1	Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose. Expert Opinion on Drug Discovery, 2011, 6, 913-920.	5.0	21
2	Protein Binding: Do We Ever Learn?. Antimicrobial Agents and Chemotherapy, 2011, 55, 3067-3074.	3.2	212
3	Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug?. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1009-1020.	3.3	27
4	Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discovery Today, 2011, 16, 822-830.	6.4	257
5	Evolution of the physicochemical properties of marketed drugs: can history foretell the future?. Drug Discovery Today, 2011, 16, 976-984.	6.4	48
6	Indolin-2-one p38α inhibitors II: Lead optimisation. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5270-5273.	2.2	14
7	The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry?. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6228-6235.	2.2	17
8	Development of a new permeability assay using lowâ€efflux MDCKII cells. Journal of Pharmaceutical Sciences, 2011, 100, 4974-4985.	3.3	254
9	A Diverted Total Synthesis of Mycolactone Analogues: An Insight into Buruli Ulcer Toxins. Chemistry - A European Journal, 2011, 17, 14413-14419.	3.3	58
10	Species Independence in Brain Tissue Binding Using Brain Homogenates. Drug Metabolism and Disposition, 2011, 39, 1270-1277.	3.3	140
11	Associating <i>in vitro</i> target binding and <i>in vivo</i> CNS occupancy of serotonin reuptake inhibitors in rats: The role of free drug concentrations. Xenobiotica, 2012, 42, 256-265.	1.1	18
12	High-Throughput 1,536-Well Fluorescence Polarization Assays for α1-Acid Glycoprotein and Human Serum Albumin Binding. PLoS ONE, 2012, 7, e45594.	2.5	21
13	The Increased Cellular Uptake and Biliary Excretion of Curcumin by Quercetin: A Possible Role of Albumin Binding Interaction. Drug Metabolism and Disposition, 2012, 40, 1452-1455.	3.3	24
14	Î ³ -Secretase Modulator in Alzheimer's Disease: Shifting the End. Journal of Alzheimer's Disease, 2012, 31, 685-696.	2.6	32
17	Role of mixed ion channel effects in the cardiovascular safety assessment of the novel antiâ€MRSA fluoroquinolone JNJâ€Q2. British Journal of Pharmacology, 2012, 166, 1694-1707.	5.4	13
18	Structure–Activity Relationship of Nonacidic Quinazolinone Inhibitors of Human Microsomal Prostaglandin Synthase 1 (mPGESÂ1). Journal of Medicinal Chemistry, 2012, 55, 3792-3803.	6.4	49
19	Relating Molecular Properties and in Vitro Assay Results to in Vivo Drug Disposition and Toxicity Outcomes. Journal of Medicinal Chemistry, 2012, 55, 6455-6466.	6.4	55
20	Human serum albumin: From bench to bedside. Molecular Aspects of Medicine, 2012, 33, 209-290.	6.4	1,320

#	Article	IF	CITATIONS
21	Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4967-4974.	2.2	33
22	The right compound in the right assay at the right time: an integrated discovery DMPK strategy. Drug Metabolism Reviews, 2012, 44, 224-252.	3.6	51
23	In Vitro Measurement of Drug Efficiency Index to Aid Early Lead Optimization. Journal of Pharmaceutical Sciences, 2012, 101, 4155-4169.	3.3	30
25	Synthesis and Profiling of a Diverse Collection of Azetidine-Based Scaffolds for the Development of CNS-Focused Lead-like Libraries. Journal of Organic Chemistry, 2012, 77, 7187-7211.	3.2	109
26	Medicinal Chemistry Challenges in CNS Drug Discovery. RSC Drug Discovery Series, 2012, , 465-509.	0.3	7
27	The determination and interpretation of the therapeutic index in drug development. Nature Reviews Drug Discovery, 2012, 11, 751-761.	46.4	418
28	Selective and Potent Urea Inhibitors of Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase. Journal of Medicinal Chemistry, 2012, 55, 7759-7771.	6.4	45
29	The utility of pharmacokinetic–pharmacodynamic modeling in the discovery and optimization of selective S1P ₁ agonists. Xenobiotica, 2012, 42, 671-686.	1.1	10
30	CHAPTER 17. Crossing the Blood-brain Barrier – Methods for Evaluating CNS Exposure. RSC Drug Discovery Series, 2012, , 445-464.	0.3	1
31	Probe ADME and Test Hypotheses: a PATH beyond clearance <i>in vitro–in vivo</i> correlations in early drug discovery. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1131-1155.	3.3	12
32	What is the most important approach in current drug discovery: doing the right things or doing things right?. Drug Discovery Today, 2012, 17, 1166-1169.	6.4	21
33	Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections. Journal of Medicinal Chemistry, 2012, 55, 1662-1670.	6.4	90
34	Methods for Assessing Blood-Brain Barrier Penetration in Drug Discovery. , 2012, , 169-175.		3
36	Update on the Development of Antagonists of Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2). From Lead Optimization to Clinical Proof-of-Concept in Asthma and Allergic Rhinitis. Journal of Medicinal Chemistry, 2012, 55, 2915-2931.	6.4	70
37	Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds. Journal of Medicinal Chemistry, 2012, 55, 3667-3677.	6.4	111
38	Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections. Journal of Medicinal Chemistry, 2012, 55, 914-923.	6.4	100
39	Assessment of Biliary Clearance in Early Drug Discovery using Sandwich-cultured Hepatocyte Model. Journal of Pharmaceutical Sciences, 2012, 101, 1898-1908.	3.3	25
40	How Well Do Lipophilicity Parameters, MEEKC Microemulsion Capacity Factor, and Plasma Protein Binding Predict CNS Tissue Binding?. Journal of Pharmaceutical Sciences, 2012, 101, 1932-1940.	3.3	11

#	Article	IF	CITATIONS
41	Established and Emerging Trends in Computational Drug Discovery in the Structural Genomics Era. Chemistry and Biology, 2012, 19, 29-41.	6.0	57
42	Case study: adapting in vitro blood–brain barrier models for use in early-stage drug discovery. Drug Discovery Today, 2012, 17, 285-290.	6.4	25
43	Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Molecular and Cellular Endocrinology, 2012, 350, 310-317.	3.2	129
44	Impact of Recovery on Fraction Unbound Using Equilibrium Dialysis. Journal of Pharmaceutical Sciences, 2012, 101, 1327-1335.	3.3	52
45	Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour. Psychopharmacology, 2012, 219, 859-873.	3.1	295
46	Modeling of PET data in CNS drug discovery and development. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 267-279.	1.8	37
47	Correlation of in vitro and in vivo plasma protein binding using ultracentrifugation and UPLC-tandem mass spectrometry. Analyst, The, 2013, 138, 6106.	3.5	21
48	In vitro, in vivo and in silico models of drug distribution into the brain. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 301-314.	1.8	24
49	Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics. Current Fungal Infection Reports, 2013, 7, 89-95.	2.6	8
50	Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nature Communications, 2013, 4, 1504.	12.8	172
51	A framework incorporating the impact of exposure scenarios and application conditions on risk assessment of chemicals applied to skin. In Silico Pharmacology, 2013, 1, 10.	3.3	11
52	Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in Rat Sandwich-Cultured Hepatocytes Compared with Liver Tissue. Drug Metabolism and Disposition, 2013, 41, 1949-1956.	3.3	32
53	Study of interaction between human serum albumin and three antioxidants: Ascorbic acid, α-tocopherol, and proanthocyanidins. European Journal of Medicinal Chemistry, 2013, 70, 22-36.	5.5	77
54	Albumin–drug interaction and its clinical implication. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 5435-5443.	2.4	334
55	Strategies to Address Low Drug Solubility in Discovery and Development. Pharmacological Reviews, 2013, 65, 315-499.	16.0	1,217
57	Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. AIDS Research and Human Retroviruses, 2013, 29, 1434-1442.	1.1	14
58	Improved selectivity of ZnNa3DTPA vs. Na5DTPA to abstract Cd2+ from plasma proteins in vitro. Metallomics, 2013, 5, 615.	2.4	2
59	Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y ₁₂ Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283. Journal of Medicinal Chemistry. 2013. 56. 7015-7024.	6.4	53

		CITATION RE	PORT	
#	Article		IF	CITATIONS
60	The Clinical Relevance of Plasma Protein Binding Changes. Clinical Pharmacokinetics, 2	013, 52, 1-8.	3.5	225
61	[3 <i>a</i> ,4]-Dihydropyrazolo[1,5 <i>a</i>]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase î² Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 2	30-234.	2.8	15
62	Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous Syst Aimed for Treatment of Gastroesophageal Reflux Disease. Journal of Medicinal Chemist 220-240.	em Penetration ry, 2013, 56,	6.4	16
63	Pharmaceutical Profiling Case Study in Disruption. ACS Medicinal Chemistry Letters, 20	013, 4, 150-152.	2.8	2
64	Inflation of correlation in the pursuit of drug-likeness. Journal of Computer-Aided Moleo 2013, 27, 1-13.	cular Design,	2.9	72
65	The bioanalytical challenge of determining unbound concentration and protein binding Bioanalysis, 2013, 5, 3033-3050.	; for drugs.	1.5	58
66	ADME in Drug Discovery. , 2013, , 3-30.			5
67	PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation. Biochemical Pl 2013, 85, 1684-1699.	pr harmacology,	4.4	30
70	Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implitute the Liver. Clinical Pharmacology and Therapeutics, 2013, 94, 126-141.	ications for	4.7	228
71	Application of In Silico, In Vitro and Preclinical Pharmacokinetic Data for the Effective a Prediction of Human Pharmacokinetics. Molecular Pharmaceutics, 2013, 10, 1191-120	nd Efficient 6.	4.6	63
72	<i>In silico</i> prediction of human serum albumin binding for drug leads. Expert Opinio Discovery, 2013, 8, 583-595.	on on Drug	5.0	36
73	2-(1H-Pyrazol-4-yl)acetic acids as CRTh2 antagonists. Bioorganic and Medicinal Chemis 23, 3349-3353.	try Letters, 2013,	2.2	12
74	Rapid Measurement of Intracellular Unbound Drug Concentrations. Molecular Pharmac 10, 2467-2478.	eutics, 2013,	4.6	130
75	Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor. European Journ Chemistry, 2013, 65, 360-375.	al of Medicinal	5.5	36
76	Plasma protein binding: From discovery to development. Journal of Pharmaceutical Scie 2953-2994.	2nces, 2013, 102,	3.3	279
77	Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood Barrier—Towards a Mechanistic IVIVE-Based Approach. AAPS Journal, 2013, 15, 913-9	l–Brain 32.	4.4	42
78	Optimization of Benzoxazole-Based Inhibitors of <i>Cryptosporidium parvum</i> Inosi 5′-Monophosphate Dehydrogenase. Journal of Medicinal Chemistry, 2013, 56, 4028	ne -4043.	6.4	71
79	Discovery of 2-{3-[2-(1-lsopropyl-3-methyl-1 <i>H</i> -1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imida: (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Expo Vivo Antitumor Activity, Iournal of Medicinal Chemistry, 2013, 56, 4597-4610.	zo[1,2- <i>d</i>][1,4]oxaz sure and Robust in	epin-9-yl]-1 6.4	- - <i>H</i> -py 161

#	Article	IF	CITATIONS
80	The Use of Pseudo-Equilibrium Constant Affords Improved QSAR Models of Human Plasma Protein Binding. Pharmaceutical Research, 2013, 30, 1790-1798.	3.5	43
81	Structure–activity relationship andin vitropharmacological evaluation of imidazo[1,2-a]pyridine-based inhibitors of 5-LO. Future Medicinal Chemistry, 2013, 5, 865-880.	2.3	5
82	Reducing Drug Attrition: Safety Pharmacology. Topics in Medicinal Chemistry, 2013, , 139-158.	0.8	0
83	Demystifying Brain Penetration in Central Nervous System Drug Discovery. Journal of Medicinal Chemistry, 2013, 56, 2-12.	6.4	243
84	Effect of Alpha-1-Acid Glycoprotein Binding on Pharmacokinetics and Pharmacodynamics. Current Drug Metabolism, 2013, 14, 226-238.	1.2	27
85	Property-Based Design in the Optimisation of Benzamide Glucokinase Activators. Progress in Medicinal Chemistry, 2013, 52, 1-43.	10.4	6
86	Protein-Free Efavirenz Concentrations in Cerebrospinal Fluid and Blood Plasma Are Equivalent: Applying the Law of Mass Action To Predict Protein-Free Drug Concentration. Antimicrobial Agents and Chemotherapy, 2013, 57, 1409-1414.	3.2	45
87	Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase. Antimicrobial Agents and Chemotherapy, 2013, 57, 804-810.	3.2	39
88	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 0 0	rgBT /Ove 1.6	erlogk 10 Tf 5
88 89	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 0 0 Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21.	rgBT /Ove	rrlgçk 10 Tf 5 7
88 89 90	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 0 0 Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21. Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis). PLoS ONE, 2014, 9, e102449.	rgBT /Ove 0.6 2.5	rrl <u>og</u> k 10 Tf 5 7 27
88 89 90 91	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 0 0 Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21. Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis). PLoS ONE, 2014, 9, e102449. Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis. PLoS ONE, 2014, 9, e105222.	rgBT /Ove 0.6 2.5 2.5	erl <u>o</u> gk 10 Tf 5 7 27 23
88 89 90 91 92	 Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 0 0 Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21. Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis). PLoS ONE, 2014, 9, e102449. Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis. PLoS ONE, 2014, 9, e105222. Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. Drug Metabolism and Disposition, 2014, 42, 1780-1784. 	rgBT /Ove 0.6 2.5 2.5 3.3	erl <u>o</u> gk 10 Tf 5 7 27 23 15
88 89 90 91 92 93	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 00 Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21. Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis). PLoS ONE, 2014, 9, e102449. Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis. PLoS ONE, 2014, 9, e105222. Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. Drug Metabolism and Disposition, 2014, 42, 1780-1784. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases. Future Medicinal Chemistry, 2014, 6, 657-674.	rgBT /Ove 0.6 2.5 3.3 2.3	erlogge 10 Tf 5 7 27 23 15 8
 88 89 90 91 92 93 94 	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 00 Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21. Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis). PLoS ONE, 2014, 9, e102449. Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis. PLoS ONE, 2014, 9, e105222. Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. Drug Metabolism and Disposition, 2014, 42, 1780-1784. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases. Future Medicinal Chemistry, 2014, 6, 657-674. Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs. Xenobiotica, 2014, 44, 975-987.	rgBT /Ove 0.6 2.5 2.5 3.3 2.3 1.1	erlogge 10 Tf 5 7 27 23 15 8 6
 88 89 90 91 91 92 93 94 95 	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) Tj ETQq0 0.0 Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21. Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis). PLoS ONE, 2014, 9, e102449. Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis. PLoS ONE, 2014, 9, e105222. Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. Drug Metabolism and Disposition, 2014, 42, 1780-1784. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases. Future Medicinal Chemistry, 2014, 6, 657-674. Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs. Xenobiotica, 2014, 44, 975-987. Interactive Association of Drugs Binding to Human Serum Albumin. International Journal of Molecular Sciences, 2014, 15, 3580-3595.	rgBT /Ove 0.6 2.5 2.5 3.3 2.3 1.1 4.1	erlggk 10 Tf 5 7 27 23 15 8 6 266

Discovery of 5′â€2â€Chloroâ€<i>N</i>â€{(5,6â€dimethoxypyridinâ€2â€yl)methyl]â€2,2′:5′,3′â€terpyridineâ€3′â€ (MKâ€1064): A Selective Orexinâ€...2 Receptor Antagonist (2â€SORA) for the Treatment of Insomnia. 3.2 59 ChemMedChem, 2014, 9, 311-322.

#	Article	IF	CITATIONS
98	CHAPTER 5. Designed Macrocyclic Kinase Inhibitors. RSC Drug Discovery Series, 2014, , 141-205.	0.3	7
99	Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Frontiers in Pharmacology, 2014, 5, 174.	3.5	146
100	Drug Discovery Methods for Studying Brain Drug Delivery and Distribution. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 271-316.	0.6	2
101	Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2177-2181.	2.2	8
102	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an <i>in vitro</i> pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2014, 69, 1611-1619.	3.0	28
103	Equilibrium Gel Filtration to Measure Plasma Protein Binding of Very Highly Bound Drugs. Journal of Pharmaceutical Sciences, 2014, 103, 752-759.	3.3	13
104	Heart Regeneration: Opportunities and Challenges for Drug Discovery with Novel Chemical and Therapeutic Methods or Agents. Angewandte Chemie - International Edition, 2014, 53, 4056-4075.	13.8	36
105	A High-Throughput Cell-Based Method to Predict the Unbound Drug Fraction in the Brain. Journal of Medicinal Chemistry, 2014, 57, 3005-3010.	6.4	34
106	A Physiologically Based Modeling Strategy during Preclinical CNS Drug Development. Molecular Pharmaceutics, 2014, 11, 836-848.	4.6	26
107	Consideration of the Unbound Drug Concentration in Enzyme Kinetics. Methods in Molecular Biology, 2014, 1113, 119-145.	0.9	5
108	Development of enzyme-linked immunosorbent assay for determination of polybrominated diphenyl ether BDE-121. Analytical Biochemistry, 2014, 447, 49-54.	2.4	8
110	Estimation of the Unbound Brain Concentration of P-Glycoprotein Substrates or Nonsubstrates by a Serial Cerebrospinal Fluid Sampling Technique in Rats. Molecular Pharmaceutics, 2014, 11, 477-485.	4.6	9
111	Human serum albumin, systemic inflammation, and cirrhosis. Journal of Hepatology, 2014, 61, 396-407.	3.7	398
115	Physical Properties in Drug Design. Topics in Medicinal Chemistry, 2014, , 1-68.	0.8	13
116	Pharmacokinetics. Biochemical Pharmacology, 2014, 87, 93-120.	4.4	215
117	Species differences in drug plasma protein binding. MedChemComm, 2014, 5, 963-967.	3.4	50
118	Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy. Journal of Medicinal Chemistry, 2014, 57, 7016-7030.	6.4	81
119	Rational Use of Plasma Protein and Tissue Binding Data in Drug Design. Journal of Medicinal Chemistry, 2014, 57, 8238-8248.	6.4	135

#	Article	IF	CITATIONS
120	Understanding and Reducing the Experimental Variability of In Vitro Plasma Protein Binding Measurements. Journal of Pharmaceutical Sciences, 2014, 103, 3302-3309.	3.3	21
121	Synthesis of Tripeptides Containing <scp>d</scp> -Trp Substituted at the Indole Ring, Assessment of Opioid Receptor Binding and in Vivo Central Antinociception. Journal of Medicinal Chemistry, 2014, 57, 6861-6866.	6.4	23
122	A Systematic Assessment of Mitochondrial Function Identified Novel Signatures for Drug-Induced Mitochondrial Disruption in Cells. Toxicological Sciences, 2014, 142, 261-273.	3.1	23
123	Compartmental Models for Apical Efflux by P-glycoprotein—Part 1: Evaluation of Model Complexity. Pharmaceutical Research, 2014, 31, 347-359.	3.5	21
124	Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. European Journal of Pharmaceutical Sciences, 2014, 57, 41-47.	4.0	17
125	Influence of intensive care treatment on the protein binding of sufentanil and hydromorphone during pain therapy in postoperative cardiac surgery patients. British Journal of Anaesthesia, 2014, 113, 677-687.	3.4	10
126	Discovery of Trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as Potent, Orally Bioavailable TGR5 (GPBAR1) Agonists: Structure–Activity Relationships, Lead Optimization, and Chronic In Vivo Efficacy. Journal of Medicinal Chemistry, 2014, 57, 3263-3282.	6.4	34
127	2-(1H-Pyrazol-1-yl)acetic acids as chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes (CRTh2) antagonists. European Journal of Medicinal Chemistry, 2014, 71, 168-184.	5.5	12
128	Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099). Journal of Medicinal Chemistry, 2014, 57, 6060-6082.	6.4	57
129	Ligand efficiency metrics considered harmful. Journal of Computer-Aided Molecular Design, 2014, 28, 699-710.	2.9	54
130	Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist. ACS Medicinal Chemistry Letters, 2014, 5, 119-123.	2.8	22
131	Restricting CNS penetration of drugs to minimise adverse events: role of drug transporters. Drug Discovery Today: Technologies, 2014, 12, e79-e85.	4.0	19
132	Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3493-3498.	2.2	38
133	A simple introduction to pharmacokinetics: Part 1. NursePrescribing, 2014, 12, 497-503.	0.1	4
134	Utility of Cerebrospinal Fluid Drug Concentration as a Surrogate for Unbound Brain Concentration in Nonhuman Primates. Drug Metabolism and Pharmacokinetics, 2014, 29, 419-426.	2.2	28
136	A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. Journal of Pharmaceutical Sciences, 2015, 104, 4409-4416.	3.3	13
137	Plasma Protein Binding of Challenging Compounds. Journal of Pharmaceutical Sciences, 2015, 104, 2627-2636.	3.3	78
139	Interrogating the relationship between rat inÂvivo tissue distribution and drug property data for >200 structurally unrelated molecules. Pharmacology Research and Perspectives, 2015, 3, e00173.	2.4	28

#	Article	IF	CITATIONS
147	Characterization of plasma protein binding dissociation with online SPE-HPLC. Scientific Reports, 2015, 5, 14866.	3.3	15
148	Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window. Clinical Pharmacology and Therapeutics, 2015, 98, 76-86.	4.7	45
150	Challenges in Pharmacology Modelling. Journal of Dynamics and Differential Equations, 2015, 27, 941-959.	1.9	1
151	Influence of hepatic impairment on lenvatinib pharmacokinetics following singleâ€dose oral administration. Journal of Clinical Pharmacology, 2015, 55, 317-327.	2.0	45
152	In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacology Research and Perspectives, 2015, 3, e00175.	2.4	73
153	Unbound Ritonavir Concentrations in Rat and Human Hepatocytes. Journal of Pharmaceutical Sciences, 2015, 104, 2378-2387.	3.3	8
154	Estimation of Drug Binding to Brain Tissue: Methodology and in Vivo Application of a Distribution Assay in Brain Polar Lipids. Molecular Pharmaceutics, 2015, 12, 4529-4541.	4.6	11
155	Structure–Activity Relationship for the Oxadiazole Class of Antibiotics. Journal of Medicinal Chemistry, 2015, 58, 1380-1389.	6.4	100
156	Flavonoid interactions during digestion, absorption, distribution and metabolism: a sequential structure–activity/property relationship-based approach in the study of bioavailability and bioactivity. Drug Metabolism Reviews, 2015, 47, 175-190.	3.6	173
157	Drug–Drug Interactions Related to Altered Absorption and Plasma Protein Binding: Theoretical and Regulatory Considerations, and an Industry Perspective. Journal of Pharmaceutical Sciences, 2015, 104, 916-929.	3.3	21
158	Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism. Xenobiotica, 2015, 45, 286-301.	1.1	3
159	Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids. Journal of Biomolecular Screening, 2015, 20, 634-645.	2.6	57
160	Membrane–drug interactions studied using model membrane systems. Saudi Journal of Biological Sciences, 2015, 22, 714-718.	3.8	64
161	6-Arylpyrazine-2-carboxamides: A New Core for <i>Trypanosoma brucei</i> Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 6753-6765.	6.4	18
162	Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A. European Journal of Pharmacology, 2015, 761, 79-85.	3.5	15
163	Aurora Kinase Inhibition: A New Light in the Sky?. Journal of Medicinal Chemistry, 2015, 58, 5186-5188.	6.4	9
164	Modification of a PAMPA model to predict passive gastrointestinal absorption and plasma protein binding. European Journal of Pharmaceutical Sciences, 2015, 77, 273-278.	4.0	12
165	Integrated risk assessment of suicidal ideation and behavior in drug development. Drug Discovery Today, 2015, 20, 1135-1142.	6.4	13

#	Article	IF	CITATIONS
166	How to report and discuss ADME data in medicinal chemistry publications:in vitrodata orin vivoextrapolations?. Future Medicinal Chemistry, 2015, 7, 259-267.	2.3	1
167	Computational toxicology, friend or foe?. Toxicology Research, 2015, 4, 1159-1172.	2.1	22
168	Thermodynamics and solvent linkage of macromolecule–ligand interactions. Methods, 2015, 76, 51-60.	3.8	17
169	In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review. Advanced Drug Delivery Reviews, 2015, 86, 27-45.	13.7	92
170	Can Silicon Make an Excellent Drug Even Better? An in vitro and in vivo Headâ€toâ€Head Comparison between Loperamide and Its Silicon Analogue Sila‣operamide. ChemMedChem, 2015, 10, 911-924.	3.2	33
171	InÂvitro ADME and InÂvivo Pharmacokinetics. , 2015, , 245-306.		3
172	Development of methyl isoxazoleazepines as inhibitors of BET. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1842-1848.	2.2	22
173	Identification and Characterization of a Novel Family of Selective Antifungal Compounds (CANBEFs) That Interfere with Fungal Protein Synthesis. Antimicrobial Agents and Chemotherapy, 2015, 59, 5631-5640.	3.2	19
174	Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety. Handbook of Experimental Pharmacology, 2015, 232, 235-260.	1.8	46
175	Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. Future Medicinal Chemistry, 2015, 7, 2351-2369.	2.3	22
176	CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. Journal of Medicinal Chemistry, 2015, 58, 2584-2608.	6.4	406
177	Discovery and in Vivo Evaluation of (<i>S</i>)- <i>N</i> -(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9 <i>H</i> -purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease. Journal of Medicinal Chemistry, 2015 58 480-511	6.4	76
178	Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicology in Vitro, 2015, 29, 251-258.	2.4	22
179	Blood-Brain Barrier Methods. , 2016, , 351-369.		0
180	Selecting Good â€~Drug-Like' Properties to Optimize Small Molecule Blood-Brain Barrier Penetration. Current Medicinal Chemistry, 2016, 23, 1392-1407.	2.4	25
181	Plasma and Tissue Binding. , 2016, , 219-228.		1
182	ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia. Brazilian Journal of Medical and Biological Research, 2016, 49, e5542.	1.5	3
183	Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds. Frontiers in Pharmacology, 2016, 7, 181.	3.5	154

#	Article	IF	CITATIONS
184	Defining desirable natural product derived anticancer drug space: optimization of molecular physicochemical properties and ADMET attributes. ADMET and DMPK, 2016, 4, 98.	2.1	12
185	Study on the interaction between pelargonidinâ€3â€ <i>O</i> â€glucoside and bovine serum albumin using spectroscopic, transmission electron microscopy and molecular modeling techniques. Luminescence, 2016, 31, 442-452.	2.9	26
186	Comparison of the Exposure Time Dependence of the Activities of Synthetic Ozonide Antimalarials and Dihydroartemisinin against K13 Wild-Type and Mutant Plasmodium falciparum Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 4501-4510.	3.2	49
187	Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VXâ€770 (ivacaftor). British Journal of Pharmacology, 2016, 173, 459-470.	5.4	60
188	Effects of target binding kinetics on <i>in vivo</i> drug efficacy: k _{off} , k _{on} and rebinding. British Journal of Pharmacology, 2016, 173, 2319-2334.	5.4	94
189	Serum albumin and the haloperidol pharmacokinectics. A study using a computational model. AIP Conference Proceedings, 2016, , .	0.4	1
190	Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw553.	3.0	6
191	When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?. Drug Metabolism and Disposition, 2016, 44, 1934-1939.	3.3	35
192	Study of Small-Molecule–Membrane Protein Binding Kinetics with Nanodisc and Charge-Sensitive Optical Detection. Analytical Chemistry, 2016, 88, 2375-2379.	6.5	13
193	Dual-affinity peptide mediated inter-protein recognition. Organic and Biomolecular Chemistry, 2016, 14, 11342-11346.	2.8	6
194	Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis. European Journal of Medicinal Chemistry, 2016, 120, 353-362.	5.5	47
195	Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists. Journal of Medicinal Chemistry, 2016, 59, 4926-4947.	6.4	26
196	Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2016, 89, 31-38.	4.0	21
197	State of affairs: Design and structure–activity relationships of reversible P2Y 12 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2739-2754.	2.2	15
198	Lipophilicity and biomimetic properties measured by HPLC to support drug discovery. Journal of Pharmaceutical and Biomedical Analysis, 2016, 130, 35-54.	2.8	80
199	Mechanism of Drug-Drug Interactions Between Warfarin and Statins. Journal of Pharmaceutical Sciences, 2016, 105, 1976-1986.	3.3	34
200	Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. ACS Chemical Biology, 2016, 11, 1710-1719.	3.4	61
201	Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from <i>Pseudomonas aeruginosa</i> . Journal of Medicinal Chemistry, 2016, 59, 4790-4799.	6.4	14

#	Article	IF	CITATIONS
202	Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. Journal of Clinical Pharmacology, 2016, 56, S23-39.	2.0	86
203	Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835. Bioorganic and Medicinal Chemistry, 2016, 24, 5481-5494.	3.0	22
204	TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway. Molecular Metabolism, 2016, 5, 903-917.	6.5	49
205	Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Medicine, 2016, 5, 3176-3185.	2.8	67
206	Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 – A potential oral treatment for tuberculosis. Pulmonary Pharmacology and Therapeutics, 2016, 40, 44-51.	2.6	2
208	Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide. Molecular Therapy - Nucleic Acids, 2016, 5, e339.	5.1	28
209	Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides. Journal of Medicinal Chemistry, 2016, 59, 9686-9720.	6.4	30
210	Fluorescently Labeled Cyclodextrin Derivatives as Exogenous Markers for Real-Time Transcutaneous Measurement of Renal Function. Bioconjugate Chemistry, 2016, 27, 2513-2526.	3.6	14
211	Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma. Drug Metabolism and Disposition, 2016, 44, 1881-1889.	3.3	39
212	Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib. Molecular Cancer Therapeutics, 2016, 15, 3110-3119.	4.1	12
213	Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents. European Journal of Medicinal Chemistry, 2016, 122, 723-730.	5.5	59
215	Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacological Research, 2016, 111, 237-246.	7.1	77
216	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). Journal of Medicinal Chemistry, 2016, 59, 10891-10916.	6.4	52
217	Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA ₂). Journal of Medicinal Chemistry, 2016, 59, 10738-10749.	6.4	16
218	Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(â~'/â~') rats. Drug Metabolism and Pharmacokinetics, 2016, 31, 57-66.	2.2	10
219	Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 324-333.	2.5	19
220	Blood-Brain Barrier. , 2016, , 141-159.		2
221	Lessons Learned: Dose Selection of Small Molecule–Targeted Oncology Drugs. Clinical Cancer Research, 2016, 22, 2630-2638.	7.0	40

#	Article	IF	CITATIONS
222	Prediction of the permeability of neutral drugs inferred from their solvation properties. Bioinformatics, 2016, 32, 1163-1169.	4.1	20
223	A Comparison of LC-MS/MS and a Fully Integrated Autosampler/Solid-Phase Extraction System for the Analysis of Protein Binding Samples. Journal of Biomolecular Screening, 2016, 21, 620-625.	2.6	7
224	The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy. Contraception, 2016, 94, 104-108.	1.5	22
225	Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 253-265.	3.3	10
226	Comparative study of the effects of the structurally similar flavonoids quercetin and taxifolin on the therapeutic behavior of alprazolam. Canadian Journal of Chemistry, 2016, 94, 458-469.	1.1	10
227	Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels. Clinical Pharmacokinetics, 2016, 55, 875-887.	3.5	33
228	Fluorescent boronate-based polymer nanoparticles with reactive oxygen species (ROS)-triggered cargo release for drug-delivery applications. Nanoscale, 2016, 8, 6958-6963.	5.6	54
229	Interaction of cyanidin-3-O-glucoside with three proteins. Food Chemistry, 2016, 196, 550-559.	8.2	111
230	Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. Clinical Pharmacokinetics, 2016, 55, 143-167.	3.5	21
231	Postmortem redistribution of the heroin metabolites morphine and morphine-3-glucuronide in rabbits over 24Âh. International Journal of Legal Medicine, 2016, 130, 519-531.	2.2	20
232	Discovery of Benzotriazolo[4,3- <i>d</i>][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains. ACS Medicinal Chemistry Letters, 2016, 7, 145-150.	2.8	26
233	Insight into the interaction of antitubercular and anticancer compound clofazimine with human serum albumin: spectroscopy and molecular modelling. Journal of Biomolecular Structure and Dynamics, 2017, 35, 46-57.	3.5	44
235	Glycation alter serum albumin binding of valsartan and nateglinide when studied contemporarily. Journal of Liquid Chromatography and Related Technologies, 2017, 40, 26-35.	1.0	2
236	Zwitterionic near infrared fluorescent agents for noninvasive real-time transcutaneous assessment of kidney function. Chemical Science, 2017, 8, 2652-2660.	7.4	31
237	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. Journal of Medicinal Chemistry, 2017, 60, 3124-3153.	6.4	58
238	One-pot synthesis of reactive oxygen species (ROS)-self-immolative polyoxalate prodrug nanoparticles for hormone dependent cancer therapy with minimized side effects. Polymer Chemistry, 2017, 8, 1999-2004.	3.9	27
239	Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. Drug Metabolism and Disposition, 2017, 45, 779-789.	3.3	41
240	Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 165-230.	0.6	0

#	Article	IF	CITATIONS
241	Target Engagement Measures in Preclinical Drug Discovery: Theory, Methods, and Case Studies. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 41-80.	0.6	3
242	Quantitating drug-target engagement in single cells in vitro and in vivo. Nature Chemical Biology, 2017, 13, 168-173.	8.0	81
243	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2239-2258.	2.2	19
244	CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. Journal of Medicinal Chemistry, 2017, 60, 5943-5954.	6.4	75
245	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody. Molecular Cancer Therapeutics, 2017, 16, 1269-1278.	4.1	11
246	Novel Method to Predict In Vivo Liver-to-Plasma K _{puu} for OATP Substrates Using Suspension Hepatocytes. Drug Metabolism and Disposition, 2017, 45, 576-580.	3.3	45
247	Peptide nanoparticle with pH-sensing cargo solubility enhances cancer drug efficiency. Nano Today, 2017, 13, 15-22.	11.9	11
248	Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration. British Journal of Anaesthesia, 2017, 118, 44-57.	3.4	52
249	Antimycobacterial activity of nitrogen heterocycles derivatives: 7-(pyridine-4-yl)-indolizine derivatives. Part VII ^{8–12} . Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1291-1298.	5.2	24
250	The antitubercular activity of various nitro(triazole/imidazole)-based compounds. Bioorganic and Medicinal Chemistry, 2017, 25, 6039-6048.	3.0	20
251	Guidance on the risk assessment of substances present in food intended for infants below 16Âweeks of age. EFSA Journal, 2017, 15, e04849.	1.8	98
252	Effect of benzocaine and propranolol on phospholipid-based bilayers. Physical Chemistry Chemical Physics, 2017, 19, 32057-32071.	2.8	14
253	Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs. Journal of Pharmaceutical Sciences, 2017, 106, 3442-3452.	3.3	69
254	ADME properties evaluation in drug discovery: Prediction of plasma protein binding using NSGA-II combining PLS and consensus modeling. Chemometrics and Intelligent Laboratory Systems, 2017, 170, 84-95.	3.5	23
255	Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. Bioconjugate Chemistry, 2017, 28, 2372-2383.	3.6	27
256	Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Riskâ€Benefit Approach. Journal of Clinical Pharmacology, 2017, 57, S105-S115.	2.0	13
257	Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 869-878.	2.3	5
258	ADME in Drug Discovery. , 2017, , 39-67.		12

#	Article	IF	CITATIONS
259	Pharmacokinetics, pharmacodynamics and safety profiling of ISO1957, a preclinical candidate possessing dual activity against inflammation and nociception. Regulatory Toxicology and Pharmacology, 2017, 91, 216-225.	2.7	16
260	Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data. Pharmaceutical Research, 2017, 34, 2557-2567.	3.5	11
261	Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography. Journal of Medicinal Chemistry, 2017, 60, 7350-7370.	6.4	74
262	Preparation and Evaluation of Potent Pentafluorosulfanylâ€Substituted Antiâ€Tuberculosis Compounds. ChemMedChem, 2017, 12, 1108-1115.	3.2	16
263	L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs. Journal of Controlled Release, 2017, 261, 93-104.	9.9	62
264	Role of Passive Diffusion, Transporters, and Membrane Traffickingâ€Mediated Processes in Cellular Drug Transport. Clinical Pharmacology and Therapeutics, 2017, 101, 121-129.	4.7	28
265	The importance of protein binding for the in vitro–in vivo extrapolation (IVIVE)—example of ibuprofen, a highly protein-bound substance. Archives of Toxicology, 2017, 91, 1663-1670.	4.2	15
266	Clarification of contraceptive drug pharmacokinetics in obesity. Contraception, 2017, 95, 10-16.	1.5	21
267	Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies. Clinical Cancer Research, 2017, 23, 1080-1090.	7.0	26
268	Clinical Pharmacology Studies in Critically Ill Children. Pharmaceutical Research, 2017, 34, 7-24.	3.5	41
269	Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver. Xenobiotica, 2017, 47, 488-497.	1.1	4
270	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	6.4	47
271	Verifying the competition between haloperidol and biperiden in serum albumin through a model based on spectrofluorimetry. AIP Conference Proceedings, 2017, , .	0.4	1
272	In vitro membrane binding and protein binding (IAM MB/PB technology) to estimate in vivo distribution: applications in early drug discovery. ADMET and DMPK, 2017, 5, 14.	2.1	20
273	The Binding Effect of Proteins on Medications and Its Impact on Electrochemical Sensing: Antipsychotic Clozapine as a Case Study. Pharmaceuticals, 2017, 10, 69.	3.8	6
274	Role of ADME/PK in Drug Discovery, Safety Assessment, and Clinical Development. , 2017, , 1-33.		2
275	Antimicrobial Activity and Resistance: Influencing Factors. Frontiers in Pharmacology, 2017, 8, 364.	3.5	142
276	Quantitative Structure – Pharmacokinetics Relationships for Plasma Protein Binding of Basic Drugs. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 349	2.1	19

# 277	ARTICLE Contemporary Considerations for Discovering a Successful Medicine. , 2017, , 560-576.	IF	CITATIONS
278	A novel function of N-linked glycoproteins, alpha-2-HS-glycoprotein and hemopexin: Implications for small molecule compound-mediated neuroprotection. PLoS ONE, 2017, 12, e0186227.	2.5	13
279	Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment. , 2017, , 94-115.		3
280	ADME Optimization in Drug Discovery. , 2017, , 34-44.		2
281	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0
282	Discovery of N -arylpyrroles as agonists of GPR120 for the treatment of type II diabetes. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 841-846.	2.2	17
283	Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System. Clinical Pharmacokinetics, 2018, 57, 1059-1074.	3.5	23
284	Impact of target interactions on small-molecule drug disposition: an overlooked area. Nature Reviews Drug Discovery, 2018, 17, 299-299.	46.4	20
285	Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines. Drug Metabolism and Disposition, 2018, 46, 415-421.	3.3	32
286	Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. Future Oncology, 2018, 14, 647-663.	2.4	23
287	Why Decreasing Lipophilicity Alone Is Often Not a Reliable Strategy for Extending IV Half-life. ACS Medicinal Chemistry Letters, 2018, 9, 522-527.	2.8	30
288	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. Neurotherapeutics, 2018, 15, 742-750.	4.4	5
289	A combined photophysical and computational study on the binding of mycophenolate mofetil and its major metabolite to transport proteins. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018, 199, 308-314.	3.9	2
290	Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne. Journal of Medicinal Chemistry, 2018, 61, 4030-4051.	6.4	15
291	Approaches to measure protein binding of enzymatically unstable compounds in plasma. Bioanalysis, 2018, 10, 451-459.	1.5	4
292	New Steroidal 4-Aminoquinolines Antagonize Botulinum Neurotoxin Serotype A in Mouse Embryonic Stem Cell Derived Motor Neurons in Postintoxication Model. Journal of Medicinal Chemistry, 2018, 61, 1595-1608.	6.4	7
293	Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. European Journal of Pharmaceutical Sciences, 2018, 115, 109-118.	4.0	5
294	Surface and Solvent Dependent Adsorption of Three Neuromedin-Like Peptides in Glass and Plastic Syringes. Chromatographia, 2018, 81, 65-72.	1.3	6

#	Article	IF	CITATIONS
295	Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips. Annual Review of Pharmacology and Toxicology, 2018, 58, 37-64.	9.4	133
296	Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. Nature Communications, 2018, 9, 22.	12.8	111
297	Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Neuro-Oncology, 2018, 20, 307-312.	1.2	29
298	Poly(ethylene oxide monomethyl ether)- <i>block</i> -poly(propylene succinate) Nanoparticles: Synthesis and Characterization, Enzymatic and Cellular Degradation, Micellar Solubilization of Paclitaxel, and in Vitro and in Vivo Evaluation. Biomacromolecules, 2018, 19, 2443-2458.	5.4	11
299	Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems. Drug Discovery Today, 2018, 23, 1357-1372.	6.4	52
300	Physicochemical Properties and Structural Alerts. Methods in Pharmacology and Toxicology, 2018, , 61-76.	0.2	4
301	A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically III Patients. Clinical Pharmacokinetics, 2018, 57, 59-69.	3.5	7
302	In vivo potency revisited $\hat{a} \in $ Keep the target in sight. , 2018, 184, 177-188.		24
303	<i>Leishmania</i> and other intracellular pathogens: selectivity, drug distribution and PK–PD. Parasitology, 2018, 145, 237-247.	1.5	15
304	Ein Instrumentarium von αvâ€RGDâ€Integrinâ€Inhibitoren: Wirkstoffsuche, Herausforderungen und Möglichkeiten. Angewandte Chemie, 2018, 130, 3354-3379.	2.0	12
305	An αvâ€RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities. Angewandte Chemie - International Edition, 2018, 57, 3298-3321.	13.8	94
306	The effect of glycation on bovine serum albumin conformation and ligand binding properties with regard to gliclazide. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018, 189, 625-633.	3.9	23
307	Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico – in-vitro – in-vivo approach. Pulmonary Pharmacology and Therapeutics, 2018, 48, 151-160.	2.6	22
308	Expanding LogP: Present possibilities. Nuclear Medicine and Biology, 2018, 58, 20-32.	0.6	17
309	Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus. Journal of Medicinal Chemistry, 2018, 61, 934-945.	6.4	21
310	High in Vivo Stability of ⁶⁴ Cu-Labeled Cross-Bridged Chelators Is a Crucial Factor in Improved Tumor Imaging of RGD Peptide Conjugates. Journal of Medicinal Chemistry, 2018, 61, 385-395.	6.4	19
311	Relevance of Half-Life in Drug Design. Journal of Medicinal Chemistry, 2018, 61, 4273-4282.	6.4	107
312	Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts. Journal of Medicinal Chemistry, 2018, 61, 1767-1773.	6.4	21

	Сітатіс	on Report	
#	Article	IF	CITATIONS
313	Computational prediction of plasma protein binding of cyclic peptides from small molecule experimental data using sparse modeling techniques. BMC Bioinformatics, 2018, 19, 527.	2.6	9
314	Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models. Anti-Cancer Drugs, 2018, 29, 691-701.	1.4	1
315	Use of human induced pluripotent stem cell–derived cardiomyocytes to assess drug cardiotoxicity. Nature Protocols, 2018, 13, 3018-3041.	12.0	102
316	Introduction. Biopharmaceutics and Pharmacokinetics. , 2018, , 3-10.		2
317	Drug Distribution. , 2018, , 33-53.		2
318	Risdiplam distributes and increases <scp>SMN</scp> protein in both the central nervous system and peripheral organs. Pharmacology Research and Perspectives, 2018, 6, e00447.	2.4	109
319	Testing for drug-human serum albumin binding using fluorescent probes and other methods. Expert Opinion on Drug Discovery, 2018, 13, 1005-1014.	5.0	17
320	The impact of low temperature on fraction unbound for plasma and tissue. Biopharmaceutics and Drug Disposition, 2018, 39, 437-442.	1.9	19
321	Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	3
322	Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS ONE, 2018, 13, e0202436.	2.5	11
323	Discovery of (<i>S</i>)-3-(3-(3,5-Dimethyl-1 <i>H</i> -pyrazol-1-yl)phenyl)-4-((<i>R</i>)-3-(2-(5,6,7,8-tetrahydro-1,8-naph Acid, a Nonpeptidic α _v î² ₆ Integrin Inhibitor for the Inhaled Treatment of Idionathic Pulmonary Fibrosis, Journal of Medicinal Chemistry, 2018, 61, 8417-8443.	thyridin-2-yl)eth 6.4	yl)pyrrolidin-
324	Investigating the interaction of anticancer drug temsirolimus with human transferrin: Molecular docking and spectroscopic approach. Journal of Molecular Recognition, 2018, 31, e2728.	2.1	39
325	Utilizing postmortem drug concentrations in mechanistic modeling and simulation of cardiac effects: a proof of concept study with methadone. Toxicology Mechanisms and Methods, 2018, 28, 555-562.	2.7	1
326	Challenges with the precise prediction of ABC-transporter interactions for improved drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 697-707.	5.0	3
327	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	40
328	Importance of target-mediated drug disposition for small molecules. Drug Discovery Today, 2018, 23, 2023-2030.	6.4	15
329	Quantitative imaging of receptor-ligand engagement in intact live animals. Journal of Controlled Release, 2018, 286, 451-459.	9.9	36
331	An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. European Journal of Pharmaceutical Sciences, 2018, 123, 502-514.	4.0	63

#	Article	IF	CITATIONS
332	Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. PLoS Computational Biology, 2018, 14, e1006155.	3.2	19
333	Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. Pharmaceutics, 2018, 10, 14.	4.5	11
334	Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. Journal of Medicinal Chemistry, 2018, 61, 10345-10374.	6.4	67
335	In Vitro/In Vivo Correlation for Drug-Drug Interactions. , 2018, , 1-20.		Ο
336	Binding of sulphonylureas to plasma proteins – A KATP channel perspective. PLoS ONE, 2018, 13, e0197634.	2.5	14
337	Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells. Journal of Controlled Release, 2018, 283, 261-268.	9.9	27
338	A Novel Multiple-Read Screen for Metabolically Active Compounds Based on a Genetically Encoded FRET Sensor for ATP. SLAS Discovery, 2018, 23, 907-918.	2.7	8
339	Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice. PLoS ONE, 2018, 13, e0191225.	2.5	94
340	Biodistribution and Pharmacokinetics of Amblyomin-X, a Novel Antitumour Protein Drug in Healthy Mice. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 111-120.	1.6	8
341	Sulfonylurea derivatives and cancer, friend or foe?. European Journal of Pharmacology, 2019, 861, 172598.	3.5	25
342	The dipeptidyl peptidase-4 inhibitory effect of flavonoids is hindered in protein rich environments. Food and Function, 2019, 10, 5718-5731.	4.6	19
343	A critical view on the analysis of fluorescence quenching data for determining ligand–protein binding affinity. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 223, 117337.	3.9	45
344	Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan <i>in situ</i> in the living body. Chemical Science, 2019, 10, 8164-8170.	7.4	74
345	Potency and plasma protein binding of drugs <i>in vitro</i> —a potentially misleading pair for predicting <i>in vivo</i> efficacious concentrations in humans. Korean Journal of Physiology and Pharmacology, 2019, 23, 231.	1.2	6
346	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101828.	2.6	16
347	Computational Model To Predict the Fraction of Unbound Drug in the Brain. Journal of Chemical Information and Modeling, 2019, 59, 3251-3261.	5.4	16
348	The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance. Biomolecules, 2019, 9, 675.	4.0	15
349	Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch. Biological and Pharmaceutical Bulletin, 2019, 42, 1674-1678.	1.4	0

#	ARTICLE Simultaneous analysis of the total plasma concentration of atomastatin and its five metabolites and	IF	CITATIONS
350	the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1126-1127, 121766.	2.3	5
352	Practical approaches to evaluating and optimizing brain exposure in early drug discovery. European Journal of Medicinal Chemistry, 2019, 182, 111643.	5.5	15
353	Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1663-1674.	7.2	13
354	Strategies to optimize drug half-life in lead candidate identification. Expert Opinion on Drug Discovery, 2019, 14, 221-230.	5.0	14
355	Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis. Journal of Medicinal Chemistry, 2019, 62, 2541-2563.	6.4	16
356	Levels of Drug Targeting. , 2019, , 269-305.		17
357	The human endogenous metabolome as a pharmacology baseline for drug discovery. Drug Discovery Today, 2019, 24, 1806-1820.	6.4	9
359	Using the concordance of in vitro and in vivo data to evaluate extrapolation assumptions. PLoS ONE, 2019, 14, e0217564.	2.5	37
360	Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metabolism and Disposition, 2019, 47, 865-873.	3.3	19
361	Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. Drug Metabolism and Disposition, 2019, 47, 890-898.	3.3	21
362	Pharmacokinetic characterization of kalata B1 and related therapeutics built on the cyclotide scaffold. International Journal of Pharmaceutics, 2019, 565, 437-446.	5.2	12
363	Measurement of Free Drug Concentration from Biological Tissue by Solid-Phase Microextraction: In Silico and Experimental Study. Analytical Chemistry, 2019, 91, 7719-7728.	6.5	28
364	Avirulins, a Novel Class of HIV-1 Reverse Transcriptase Inhibitors Effective in the Female Reproductive Tract Mucosa. Viruses, 2019, 11, 408.	3.3	5
365	Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data. Pharmaceuticals, 2019, 12, 57.	3.8	10
366	Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep. PLoS ONE, 2019, 14, e0215842.	2.5	14
367	Relationship of MATE1 Inhibition and Cytotoxicity in Nephrotoxicity: Application for Safety Evaluation in Early Drug Discovery. Toxicological Sciences, 2019, 170, 223-233.	3.1	4
368	Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition. Cancer Letters, 2019, 453, 57-73.	7.2	37
369	In vitro binding of cefovecin to plasma proteins in Australian marsupials and plasma concentrations of cefovecin following single subcutaneous administration to koalas (<scp><i>Phascolarctos) Tj ETQq1 1 0.7843</i></scp>	1 4. ngBT /0	Dv e rlock 10 T

#	Article	IF	CITATIONS
370	Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. Drug Metabolism and Disposition, 2019, 47, 665-672.	3.3	31
371	Reassessing the dosing of cefoxitin prophylaxis during major abdominal surgery: insights from microdialysis and population pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy, 2019, 74, 1975-1983.	3.0	8
372	Polymyxins interaction to the human serum albumin: A thermodynamic and computational study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 217, 155-163.	3.9	16
373	The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. Frontiers in Pharmacology, 2019, 10, 199.	3.5	14
374	A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes. Drug Metabolism and Disposition, 2019, 47, 484-492.	3.3	38
375	A novel method using nuclear magnetic resonance for plasma protein binding assessment in drug discovery programs. Journal of Pharmaceutical and Biomedical Analysis, 2019, 167, 21-29.	2.8	11
376	Pharmacokinetic evaluation of medicinally important synthetic N,N′ diindolylmethane glucoside: Improved synthesis and metabolic stability. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1007-1011.	2.2	7
377	Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. PLoS Computational Biology, 2019, 15, e1006740.	3.2	21
378	A Newly Discovered Phenylethanoid Glycoside from Stevia rebaudiana Bertoni Affects Insulin Secretion in Rat INS-1 Islet β Cells. Molecules, 2019, 24, 4178.	3.8	17
379	Applying Two Orthogonal Methods to Assess Accuracy of Plasma Protein Binding Measurements for Highly Bound Compounds. Journal of Pharmaceutical Sciences, 2019, 108, 3745-3749.	3.3	8
380	Fluorination as tool to improve bioanalytical sensitivity and COX-2-selective antitumor activity of cobalt alkyne complexes. Dalton Transactions, 2019, 48, 15856-15868.	3.3	25
381	VAS2870 and VAS3947 attenuate platelet activation and thrombus formation via a NOX-independent pathway downstream of PKC. Scientific Reports, 2019, 9, 18852.	3.3	18
382	The antagonism of folate receptor by dolutegravir. Aids, 2019, 33, 1967-1976.	2.2	31
383	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. Transplantation, 2019, 103, 2012-2030.	1.0	43
384	Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities. Drug Metabolism and Disposition, 2019, 47, 1122-1135.	3.3	79
385	Dynamic Combinatorial Chemistry: A New Methodology Comes of Age. Chemistry - A European Journal, 2019, 25, 60-73.	3.3	86
386	Highly reproducible and fast detection of 6-thioguanine in human serum using a droplet-based microfluidic SERS system. Sensors and Actuators B: Chemical, 2019, 283, 532-537.	7.8	36
387	In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds. Archives of Toxicology, 2019, 93, 401-416.	4.2	59

#	Article	IF	CITATIONS
388	Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein. Pharmaceutical Research, 2019, 36, 30.	3.5	88
389	Nongenotoxic 3-Nitroimidazo[1,2- <i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity. ACS Medicinal Chemistry Letters, 2019, 10, 34-39.	2.8	31
390	Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	41
391	Drug sales confirm clinical advantage of multiâ€ŧarget inhibition of drug escapes by anticancer kinase inhibitors. Drug Development Research, 2019, 80, 246-252.	2.9	1
392	A simple model to solve a complex drug toxicity problem. Toxicology Research, 2019, 8, 157-171.	2.1	16
393	Direct determination of free state low molecular weight compounds in serum by online TurboFlow SPE HPLC-MS/MS and its application. Talanta, 2019, 194, 960-968.	5.5	9
394	Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species. Xenobiotica, 2019, 49, 1192-1201.	1.1	30
395	Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action. European Journal of Medicinal Chemistry, 2019, 162, 32-50.	5.5	15
396	Addressing Antimicrobial Resistance through New Medicinal and Synthetic Chemistry Strategies. SLAS Discovery, 2019, 24, 419-439.	2.7	10
397	Plasma Protein Binding of Highly Bound Drugs Determined With Equilibrium Gel Filtration of Nonradiolabeled Compounds and LC-MS/MS Detection. Journal of Pharmaceutical Sciences, 2019, 108, 1053-1060.	3.3	17
398	Clearance in Drug Design. Journal of Medicinal Chemistry, 2019, 62, 2245-2255.	6.4	99
399	Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery. Xenobiotica, 2020, 50, 270-279.	1.1	8
400	A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model. Journal of Drug Targeting, 2020, 28, 419-427.	4.4	6
401	Evaluation of Fraction Unbound Across 7 Tissues of 5 Species. Journal of Pharmaceutical Sciences, 2020, 109, 1178-1190.	3.3	20
402	Influence of transporters in treating cancers in the CNS. , 2020, , 277-301.		2
403	Structural attributes influencing unbound tissue distribution. European Journal of Medicinal Chemistry, 2020, 185, 111813.	5.5	19
404	Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor. Nuclear Medicine and Biology, 2020, 82-83, 1-8.	0.6	1
405	Letter to the editor re. Aids, 2020, 34, 162-163.	2.2	1

#	Article	IF	CITATIONS
406	Antimycobacterial activity of azepanobetulin and its derivative: In vitro, in vivo, ADMET and docking studies. Bioorganic Chemistry, 2020, 104, 104209.	4.1	13
407	Progress of derisking strategies for drug-induced liver injury (DILI) in the last two decades. , 2020, , 487-506.		ο
408	Application of HPLC measurements for the determination of physicochemical and biomimetic properties to model inÂvivo drug distribution in support of early drug discovery. Handbook of Analytical Separations, 2020, 8, 667-758.	0.8	3
409	Insights into the Binding of Dietary Phenolic Compounds to Human Serum Albumin and Food-Drug Interactions. Pharmaceutics, 2020, 12, 1123.	4.5	33
410	Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations. Regulatory Toxicology and Pharmacology, 2020, 117, 104756.	2.7	24
411	Physiologicallyâ€Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS oVâ€2. Clinical Pharmacology and Therapeutics, 2020, 108, 1176-1184.	4.7	6
412	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 9093-9126.	6.4	41
413	Blood distribution and plasma protein binding of PHOTOCYANINE: a promising phthalocyanine photosensitizer inphaseâ; clinical trials. European Journal of Pharmaceutical Sciences, 2020, 153, 105491.	4.0	9
414	Parameter Estimation and Reporting in Noncompartmental Analysis of Clinical Pharmacokinetic Data. Clinical Pharmacology in Drug Development, 2020, 9, S5-S35.	1.6	3
415	Organic Cation Transporter 1 and 3 Contribute to the High Accumulation of Dehydrocorydaline in the Heart. Drug Metabolism and Disposition, 2020, 48, 1074-1083.	3.3	16
416	Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127428.	2.2	2
417	From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies. Molecules, 2020, 25, 3320.	3.8	21
418	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVIDâ€19 Therapeutic Development. Clinical Pharmacology and Therapeutics, 2021, 110, 64-68.	4.7	21
419	Methods to optimize CNS exposure of drug candidates. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127503.	2.2	9
420	Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Frontiers in Pharmacology, 2020, 11, 01021.	3.5	345
421	Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. Virologica Sinica, 2020, 35, 776-784.	3.0	24
422	Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase. Journal of Medicinal Chemistry, 2020, 63, 11882-11901.	6.4	11
423	Synthesis and biological properties of a series of aryl alkyl disulfide derivatives. Heliyon, 2020, 6, e05368.	3.2	6

#	Article	IF	CITATIONS
424	Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	5
425	Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection by Mycobacterium tuberculosis. Frontiers in Pharmacology, 2020, 11, 724.	3.5	6
426	Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 189-198.	1.8	24
427	<i>In vivo</i> pharmacokinetics, distribution, and excretion of an anticancer agent isolated from red ginseng, in rat. Xenobiotica, 2020, 50, 1323-1331.	1.1	6
428	Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone. Archives of Toxicology, 2020, 94, 2809-2827.	4.2	17
429	A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling. Assay and Drug Development Technologies, 2020, 18, 157-179.	1.2	22
430	Can image analysis provide evidence that lysosomal sequestration mediates daunorubicin resistance?. Chemico-Biological Interactions, 2020, 327, 109138.	4.0	5
431	Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. Molecular Pharmaceutics, 2020, 17, 2299-2309.	4.6	33
432	An interim internal Threshold of Toxicologic Concern (iTTC) for chemicals in consumer products, with support from an automated assessment of ToxCastâ,,¢ dose response data. Regulatory Toxicology and Pharmacology, 2020, 114, 104656.	2.7	12
433	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathologica Communications, 2020, 8, 78.	5.2	28
434	Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes. Pharmaceutics, 2020, 12, 417.	4.5	17
435	Advances in therapeutic peptides targeting G protein-coupled receptors. Nature Reviews Drug Discovery, 2020, 19, 389-413.	46.4	162
436	Protein Binding and Stability of Drug Candidates: The Achilles' Heel in In Vitro Potency Assays. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 427-432.	1.6	1
437	Physicochemical and Pharmacokinetic Analysis of Anacardic Acid Derivatives. ACS Omega, 2020, 5, 6021-6030.	3.5	44
438	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization. Journal of Medicinal Chemistry, 2020, 63, 12156-12170.	6.4	56
439	Structure-activity analysis of truncated albumin-binding domains suggests new lead constructs for potential therapeutic delivery. Journal of Biological Chemistry, 2020, 295, 12143-12152.	3.4	6
440	Efficacy, metabolism and pharmacokinetics of Ro 15-5458, a forgotten schistosomicidal 9-acridanone hydrazone. Journal of Antimicrobial Chemotherapy, 2020, 75, 2925-2932.	3.0	3
441	Nrp1 is Activated by Konjac Ceramide Binding-Induced Structural Rigidification of the a1a2 Domain. Cells, 2020, 9, 517.	4.1	2

ARTICLE IF CITATIONS # Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as 442 6.4 9 Potent Senescence-Inducing Anti-Cancer Agents. Journal of Medicinal Chemistry, 2020, 63, 4655-4684. Anionic versus neutral Pt(II) complexes: The relevance of the charge for human serum albumin 443 3.5 binding. Journal of Inorganic Biochemistry, 2020, 206, 111024. Binding of adenosine derivatives to carrier proteins may reduce their antiplatelet activity. 444 4.4 6 Biochemical Pharmacology, 2020, 174, 113827. Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies. Drug Discovery Today, 2020, 25, 909-919. 445 6.4 <i>Bis</i>-(imidazole/benzimidazole)-pyridine derivatives: synthesis, structure and antimycobacterial 446 2.3 33 activity. Future Medicinal Chemistry, 2020, 12, 207-222. Does <i>In Vitro</i> Potency Predict Clinically Efficacious Concentrations?. Clinical Pharmacology and Therapeutics, 2020, 108, 298-305. 4.7 Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine. 448 4.2 19 Archives of Toxicology, 2020, 94, 2009-2025. An adapted LC-MS/MS method for the determination of free plasma concentration of cefoperazone in children: Age-dependent protein binding. Journal of Chromatography B: Analytical Technologies in the 2.3 Biomedical and Life Sciences, 2020, 1144, 122081. Description of Druglike Properties of Safranal and Its Chemistry behind Low Oral Exposure. ACS 450 3.5 13 Omega, 2020, 5, 9885-9891. Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats. Pharmacology Research and Perspectives, 2020, 2.4 8, e00575. Fundamental aspects of DMPK optimization of targeted protein degraders. Drug Discovery Today, 2020, 452 6.4 87 25, 969-982. Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of 3.3 Distribution Predictions in the Rat. Drug Metabolism and Disposition, 2021, 49, 53-61. Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and 454 1.1 4 humanized TK-NOG mouse. Xenobiotica, 2021, 51, 51-60. Plasma protein binding, metabolism, reaction phenotyping and toxicokinetic studies of fenarimol after 1.1 oral and intravenous administration in rats. Xenobiotica, 2021, 51, 72-81. Serum protein-based nanoparticles for cancer diagnosis and treatment. Journal of Controlled 456 9.9 89 Release, 2021, 329, 997-1022. Serum albumin: clinical significance of drug binding and development as drug delivery vehicle. 2.3 Advances in Protein Chemistry and Structural Biology, 2021, 123, 193-218. Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of 458 3.3 20 Structurally Diverse Clinical Compounds. Drug Metabolism and Disposition, 2021, 49, 169-178. Biological Screening and Radiolabeling of Raptinal as a Potential Anticancer Novel Drug in Hepatocellular Carcinoma Model. European Journal of Pharmaceutical Sciences, 2021, 158, 105653.

		CITATION RE	EPORT	
#	Article		IF	Citations
460	Enabling direct and definitive free fraction determination for highly-bound compounds i binding assay. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113765.	n protein	2.8	4
461	Target Validation Using PROTACs: Applying the Four Pillars Framework. SLAS Discovery, 474-483.	2021, 26,	2.7	22
462	Systematic Analysis of Protein Targets Associated with Adverse Events of Drugs from Cl and Postmarketing Reports. Chemical Research in Toxicology, 2021, 34, 365-384.	inical Trials	3.3	13
463	Target Validationâ \in "Prosecuting the Target. , 2021, , .			Ο
464	Pharmacological Screening: Drug Discovery. , 2021, , 211-233.			2
465	Determination of Fraction Unbound and Unbound Partition Coefficient to Estimate Intra Drug Concentration. Methods in Pharmacology and Toxicology, 2021, , 81-96.	acellular Free	0.2	3
466	CHAPTER 1. Overview of Strategies for Solving ADMET Challenges. RSC Drug Discovery 1-15.	Series, 2021, ,	0.3	5
467	Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in G binding model. European Journal of Clinical Pharmacology, 2021, 77, 999-1009.	China: a protein	1.9	7
468	Holistic Assessment of Compound Propertiesâ \in "In Vitro to In Vivo Pharmacology. , 202	1,,.		0
469	Drug Binding to Plasma Proteins. , 2021, , 1-12.			0
470	Free Drug Theory. , 2021, , 1-6.			1
471	ABC Transporters: Drug Transfer Across Cellular Interfaces. , 2021, , 1-8.			0
472	Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient. , 2021, , 1-6.			0
473	Quantitative Analysis of Intracellular Drug Concentrations in Hepatocytes. Methods in F and Toxicology, 2021, , 97-125.	Pharmacology	0.2	0
474	NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Science Translational Medic	ine, 2021, 13, .	12.4	43
475	Human Plasma In ell Western Assays—An In vitro Predictor for In vivo Pharmacolog Drug Discovery. Current Protocols, 2021, 1, e51.	y in Oncology	2.9	0
476	Nonspecific Binding Considerations in the Rational Design and Development of Small M COVIDâ€19 Therapeutics. Clinical Pharmacology and Therapeutics, 2021, 110, 294-296	olecule	4.7	4
477	The influence of calculated physicochemical properties of compounds on their ADMET p Bioorganic and Medicinal Chemistry Letters, 2021, 36, 127825.	profiles.	2.2	2

#	Article	IF	Citations
478	Hepatic transporterâ€mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory recommendations. Biopharmaceutics and Drug Disposition, 2021, 42, 45-77.	1.9	3
479	Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors. Cancer Chemotherapy and Pharmacology, 2021, 88, 89-98.	2.3	2
481	Actives from MMV Open Access Boxes? A suggested way forward. PLoS Pathogens, 2021, 17, e1009384.	4.7	12
482	A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. Journal of Medicinal Chemistry, 2021, 64, 4841-4856.	6.4	10
483	Multi-spectroscopic and molecular docking studies for binding interaction between fluvoxamine and human serum albumin. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 252, 119495.	3.9	28
484	Protein suppresses both bitterness and oleocanthal-elicited pungency of extra virgin olive oil. Scientific Reports, 2021, 11, 11851.	3.3	5
485	Nonspecific Binding—Fundamental Concepts and Consequences for Biosensing Applications. Chemical Reviews, 2021, 121, 8095-8160.	47.7	113
486	Investigating the glucuronidation and sulfation pathways contribution and disposition kinetics of Bisphenol S and its metabolites using LC-MS/MS-based nonenzymatic hydrolysis method. Chemosphere, 2021, 273, 129624.	8.2	8
487	Effective exposure of chemicals in in vitro cell systems: A review of chemical distribution models. Toxicology in Vitro, 2021, 73, 105133.	2.4	58
488	Endogenous Conjugation of Biomimetic Dinitrosyl Iron Complex with Protein Vehicles for Oral Delivery of Nitric Oxide to Brain and Activation of Hippocampal Neurogenesis. Jacs Au, 2021, 1, 998-1013.	7.9	24
489	Albumin roles in developing anticancer compounds. Medicinal Chemistry Research, 2021, 30, 1469-1495.	2.4	8
490	Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. Bioanalysis, 2021, 13, 1101-1111.	1.5	2
491	Comprehensive overview of human serum albumin glycation in diabetes mellitus. World Journal of Diabetes, 2021, 12, 1057-1069.	3.5	23
492	Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent. Molecular Cancer Therapeutics, 2021, 20, 1846-1857.	4.1	13
493	Pharmacological, Pharmacokinetic, Pharmacodynamic and Physicochemical Characterization of FE 205030: A Potent, Fast Acting, Injectable CGRP Receptor Antagonist for the Treatment of Acute Episodic Migraine. Journal of Pharmaceutical Sciences, 2021, , .	3.3	4
494	Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opinion on Investigational Drugs, 2021, 30, 681-694.	4.1	28
495	Ligand binding at the protein–lipid interface: strategic considerations for drug design. Nature Reviews Drug Discovery, 2021, 20, 710-722.	46.4	59
496	Evolving approaches on measurements and applications of intracellular free drug concentration and Kp _{uu} in drug discovery. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 733-746.	3.3	8

#	Article	IF	CITATIONS
497	Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry, 2021, 64, 11090-11128.	6.4	11
498	In vivo-in vitro correlation of antitumor activity of heat shock protein 90 (HSP90) inhibitors with a pharmacokinetics/pharmacodynamics analysis using NCI-N87 xenograft mice. Xenobiotica, 2021, 51, 968-976.	1.1	0
499	BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. Journal of Medicinal Chemistry, 2021, 64, 12723-12737.	6.4	6
500	Discovery and Characterization of a Rapidly Fungicidal and Minimally Toxic Peptoid against Cryptococcus neoformans. ACS Medicinal Chemistry Letters, 2021, 12, 1470-1477.	2.8	3
501	Current insights into epigenetics, noncoding RNA interactome and clinical pharmacokinetics of dietary polyphenols in cancer chemoprevention. Critical Reviews in Food Science and Nutrition, 2023, 63, 1755-1791.	10.3	37
502	Concentrations of vatinoxan and xylazine in plasma, cerebrospinal fluid and brain tissue following intravenous administration in sheep. Veterinary Anaesthesia and Analgesia, 2021, 48, 900-905.	0.6	1
503	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0239920.	3.2	10
505	Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine. Pharmaceutics, 2021, 13, 1261.	4.5	14
506	An update on the importance of plasma protein binding in drug discovery and development. Expert Opinion on Drug Discovery, 2021, 16, 1453-1465.	5.0	30
507	Optimizing a High-Throughput Solid-Phase Microextraction System to Determine the Plasma Protein Binding of Drugs in Human Plasma. Analytical Chemistry, 2021, 93, 11061-11065.	6.5	24
509	Pterostilbene Attenuates Particulate Matter-Induced Oxidative Stress, Inflammation and Aging in Keratinocytes. Antioxidants, 2021, 10, 1552.	5.1	18
510	Discovery of potential HER2 inhibitors from <i>Mangifera indica</i> for the treatment of HER2-Positive breast cancer: an integrated computational approach. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12772-12784.	3.5	18
511	Gold Nanoparticles-Amplified Indirect Competitive Enzyme-Linked Immunosorbent Assay of BDE-121 Using a Monoclonal Antibody. Journal of Nanoscience and Nanotechnology, 2021, 21, 5036-5043.	0.9	2
512	Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States. Journal of Pharmaceutical Sciences, 2021, 110, 3331-3344.	3.3	18
513	Plasma Protein Binding Drug Interactions. , 2021, , 1-11.		0
515	Insights into flibanserin oxidative stress degradation pathway: <i>in silico</i> – <i>in vitro</i> toxicity assessment of its degradates. New Journal of Chemistry, 2021, 45, 2620-2630.	2.8	5
516	Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 163-172.	1.6	10
517	Consideration of the Unbound Drug Concentration in Enzyme Kinetics. Methods in Molecular Biology, 2021, 2342, 113-145.	0.9	2

		15	0
#	ARTICLE Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the Old to the New	IF	CITATIONS
518	Paradigm and Assessment of Drug–Transporter Interactions. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 339-374.	0.6	4
519	Introduction to Drug-Drug Interactions. , 2018, , 1-13.		1
520	Hypoalbuminaemia and Altered Protein Binding. , 2018, , 73-99.		1
521	Models for Nonspecific Binding and Partitioning. RSC Drug Discovery Series, 2015, , 53-65.	0.3	1
522	Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain. Pain, 2021, 162, 1250-1261.	4.2	13
523	Uncovering the molecular and physiological processes of anticancer leads binding human serum albumin: A physical insight into drug efficacy. PLoS ONE, 2017, 12, e0176208.	2.5	24
524	Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. Current Medicinal Chemistry, 2019, 26, 4454-4475.	2.4	41
525	Studies on Drug – Human Serum Albumin Binding: The Current State of the Matter. Current Pharmaceutical Design, 2015, 21, 1817-1830.	1.9	70
526	Advances in Drug Discovery and Development for Pediatric Tuberculosis. Mini-Reviews in Medicinal Chemistry, 2016, 16, 481-497.	2.4	11
527	Multifaceted Factors Causing Conflicting Outcomes in Herb-Drug Interactions. Pharmaceutics, 2021, 13, 43.	4.5	22
528	Recent Advances on Nanotechnology Applications to Cancer Drug Therapy. Journal of Cancer Research Updates, 0, , .	0.3	1
529	The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. ELife, 2016, 5, .	6.0	67
530	Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition. ACS Medicinal Chemistry Letters, 2021, 12, 1861-1865.	2.8	16
531	Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats. Pharmacology Research and Perspectives, 2021, 9, e00879.	2.4	2
532	Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1281-1292.	3.3	44
533	Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane® in rodent and non-human primate models using a stable isotope tracer assay. Biomaterials, 2021, 278, 121140.	11.4	15
534	ADVANCES IN APPLICATIONS OF NANOTECHNOLOGY TO DRUG DELIVERY. , 2013, , 1-24.		0
535	Microglial Biology in Neuroinflammatory Disease: Pharmaco-industrial Approach to Target Validation.		2

#	Article	IF	CITATIONS
536	Estimation of angiotensin-converting enzyme inhibitors protein binding degree using chromatographic hydrophobicity data. Srpski Arhiv Za Celokupno Lekarstvo, 2015, 143, 50-55.	0.2	2
537	Drug–Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspective. RSC Drug Discovery Series, 2015, , 263-282.	0.3	Ο
538	Assessing Therapeutic Index. , 2017, , 87-93.		1
539	An Introduction toÂPharmacokinetics. , 2017, , 13-46.		0
541	Pharmacokinetic profiles reconcile in vitro and in vivo activities of novel trypanocidal compounds. Matters, 0, , .	1.0	0
542	Drug Discovery and Development. , 2019, , 87-136.		0
544	In Vitro/In Vivo Correlation for Drug-Drug Interactions. , 2020, , 847-866.		0
546	Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 39.	1.0	2
547	OFM-recirculation and OFM-suction: advanced in-vivo open flow microperfusion (OFM) methods for direct and absolute quantification of albumin in interstitial fluid. Biomedical Physics and Engineering Express, 2020, 6, 065031.	1.2	6
549	Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188655.	7.4	13
550	The role of DMPK science in improving pharmaceutical research and development efficiency. Drug Discovery Today, 2022, 27, 705-729.	6.4	7
551	Rational Design of Anti-Angiogenic Peptides to Inhibit VEGF/VEGFR2 Interactions for Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	1.7	0
552	Free Drug Theory. , 2022, , 1-6.		0
553	The inhibition of interaction with serum albumin enhances the physiological activity of curcumin by increasing its cellular uptake. Food and Function, 2022, 13, 639-648.	4.6	5
554	Effect of topical berberine in murine cutaneous leishmaniasis lesions. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	0
555	Drug Interaction between Dexamethasone and Ketoprofen with Thiopental in Male Dogs: Effect on the Recovery from Anesthesia and Pharmacokinetics Parameters. Veterinary Medicine International, 2022, 2022, 1-8.	1.5	0
556	Toward better assessments of developmental toxicity using stem cellâ€based in vitro embryogenesis models. Birth Defects Research, 2022, 114, 972-982.	1.5	7
557	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. MBio, 2021, 12, e0334721.	4.1	45

#	Article	IF	CITATIONS
558	Magnetic nanoparticles and their application in bioanalysis. , 2022, , 413-445.		0
560	Design, Molecular Docking Studies and ADMET Prediction of Chalcones of Indole-Benzenesulfonyl Derivatives as Thioredoxin Inhibitor for Anticancer Activity. Journal of Computational Biophysics and Chemistry, 2022, 21, 361-371.	1.7	1
561	PET as a Translational Tool in Drug Development for Neuroscience Compounds. Clinical Pharmacology and Therapeutics, 2022, 111, 774-785.	4.7	7
562	Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment. Journal of Clinical Pharmacology, 2021, , .	2.0	1
563	Silymarin from Milk Thistle Fruits Counteracts Selected Pathological Changes in the Lenses of Type 1 Diabetic Rats. Nutrients, 2022, 14, 1450.	4.1	2
564	Guide to development of compound files for <scp>PBPK</scp> modeling in the Simcyp populationâ€based simulator. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 805-821.	2.5	21
565	Possible Extraction of Drugs from Lung Tissue During Broncho-alveolar Lavage Suggest Uncertainty in the Procedure's Utility for Quantitative Assessment of Airway Drug Exposure. Journal of Pharmaceutical Sciences, 2022, 111, 852-858.	3.3	4
566	Cytochrome P450 isoforms contribution, plasma protein binding, toxicokinetics of enniatin A in rats and in vivo clearance prediction in humans. Food and Chemical Toxicology, 2022, 164, 112988.	3.6	4
567	Deciphering albumin-directed drug delivery by imaging. Advanced Drug Delivery Reviews, 2022, 185, 114237.	13.7	25
568	Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. Viruses, 2022, 14, 69.	3.3	5
569	"Clickable―Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. Journal of Medicinal Chemistry, 2022, 65, 710-733.	6.4	13
570	Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development. Pharmaceutical Research, 2022, 39, 1321-1341.	3.5	31
576	Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Science Advances, 2022, 8, eabl6339.	10.3	6
577	In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis. Frontiers in Pharmacology, 2022, 13, .	3.5	2
578	Predicting Approximate Clinically Effective Doses in Oncology Using Preclinical Efficacy and Body Surface Area Conversion: A Retrospective Analysis. Frontiers in Pharmacology, 2022, 13, 830972.	3.5	1
580	IDL-PPBopt: A Strategy for Prediction and Optimization of Human Plasma Protein Binding of Compounds via an Interpretable Deep Learning Method. Journal of Chemical Information and Modeling, 2022, 62, 2788-2799.	5.4	9
582	The importance of plasma protein and tissue binding in a drug discovery program to successfully deliver a preclinical candidate. Progress in Medicinal Chemistry, 2022, , 163-214.	10.4	5
583	Plasma Protein Binding Drug Interactions. , 2022, , 1019-1028.		0

#	Article	IF	CITATIONS
584	Free Drug Theory. , 2022, , 492-498.		0
585	Drug Binding to Plasma Proteins. , 2022, , 315-326.		0
586	Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient. , 2022, , 217-222.		0
587	ABC Transporters: Drug Transfer Across Cellular Interfaces. , 2022, , 11-18.		1
588	Considerations and recommendations for assessment of plasma protein binding and drug–drug interactions for siRNA therapeutics. Nucleic Acids Research, 2022, 50, 6020-6037.	14.5	20
589	Antibacterial Activity against Clinical Isolates and In Vivo Efficacy of Coralmycins. Antibiotics, 2022, 11, 902.	3.7	2
590	Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences. Antibiotics, 2022, 11, 923.	3.7	9
591	Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 621-637.	1.6	2
592	Elucidation on inhibition and binding mechanism of bovine liver catalase by nifedipine: multiâ€ s pectroscopic analysis and computer simulation methods. Luminescence, 0, , .	2.9	0
593	Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue) Tj ETQq1	1 0.78431 6.4	.4 _. rgBT /Ove
594	Optimized scaling of translational factors in oncology: from xenografts to RECIST. Cancer Chemotherapy and Pharmacology, 2022, 90, 239-250.	2.3	1
595	A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate. Frontiers in Molecular Biosciences, 0, 9, .	3.5	3
596	Murine Central Nervous System and Bone Marrow Distribution of the Aurora A Kinase Inhibitor Alisertib: Pharmacokinetics and Exposure at the Sites of Efficacy and Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2022, 383, 44-55.	2.5	5
597	Binding and mechanistic studies of 5-HT7 specific benzothiazolone derivatives with bovine serum albumin: Spectroscopic and in silico studies. Journal of Molecular Liquids, 2022, 366, 120143.	4.9	3
598	Comprehending binding features between ibrutinib and Human Alpha-1 acid glycoprotein: Combined experimental approaches and theoretical simulations. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023, 285, 121834.	3.9	7
599	Molecular docking analysis of estrogen receptor binding phytocomponents identified from the ethyl acetate extract of Salicornia herbacea (L). Bioinformation, 2022, 18, 273-283.	0.5	2
600	In Silico Screening of Active Compounds in Garri for the Inhibition of Key Enzymes Linked to Diabetes Mellitus. ACS Food Science & Technology, 2022, 2, 1597-1611.	2.7	5
601	Time matters – <i>inÂvitro</i> cellular disposition kinetics help rationalizing cellular potency disconnects. Xenobiotica, 2022, 52, 878-889.	1.1	3

#	Article	IF	CITATIONS
603	Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer Treatment Reviews, 2022, 110, 102466.	7.7	4
604	ZWIÄ",ZKI WIÄ",ŻĄ,CE SIÄ [~] Z BIAÅKAMI OSOCZA U LUDZI. ZNACZENIE W TERAPII ORAZ METODY OZNACZANIA FRAKCJI. , 2017, 15, 50-59.	WOLNEJ	1
605	What Makes a Potent Nitrosamine? Statistical Validation of Expert-Derived Structure–Activity Relationships. Chemical Research in Toxicology, 2022, 35, 1997-2013.	3.3	24
606	Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide. Journal of the American Chemical Society, 2022, 144, 19485-19498.	13.7	0
607	Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: both are potent and selective covalent BTK inhibitors . Journal of Pharmacology and Experimental Therapeutics, 0, , JPET-AR-2022-001116.	2.5	1
608	ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs). Xenobiotica, 2022, 52, 770-785.	1.1	2
609	Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection. Journal of Pharmaceutical Analysis, 2023, 13, 255-261.	5.3	7
611	DMPK Lead Optimization. , 2022, , 63-139.		0
612	The era of high-quality chemical probes. RSC Medicinal Chemistry, 2022, 13, 1446-1459.	3.9	15
613	Albumin-based nanodevices for breast cancer diagnosis and therapy. Journal of Drug Delivery Science and Technology, 2023, 79, 104072.	3.0	7
614	A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies. Xenobiotica, 2022, 52, 786-796.	1.1	1
615	Plasma Protein Binding Refinement of the Extended Clearance Classification System: Subclasses for Predicting Hepatic Uptake or Renal Clearance for Classes 1B and 3B. European Journal of Drug Metabolism and Pharmacokinetics, 0, , .	1.6	0
616	Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability. International Journal of Molecular Sciences, 2022, 23, 15029.	4.1	2
619	Special issue on applications of in vitro, in vivo, and modeling and simulation tools for central nervous system drug disposition. Biopharmaceutics and Drug Disposition, 2023, 44, 3-6.	1.9	0
620	Determination of free and total meropenem levels in human plasma and its application for the consistency evaluation of generic drugs. Rapid Communications in Mass Spectrometry, 2023, 37, .	1.5	1
623	Addressing the Accuracy of Plasma Protein Binding Measurement for Highly Bound Compounds Using the Dilution Method. AAPS Journal, 2023, 25, .	4.4	1
624	Assessment of Epithelial Lining Fluid Partitioning of Systemically Administered Monoclonal Antibodies in Rats. Journal of Pharmaceutical Sciences, 2023, 112, 1130-1136.	3.3	0
625	Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance. Pharmacological Reviews, 2023, 75, 416-462.	16.0	2

#	Article	IF	CITATIONS
626	Real-time monitoring of polymyxin B-sodium deoxycholate sulfate binding with immobilized human serum albumin by surface plasmon resonance. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2023, 660, 130816.	4.7	3
627	Metallodrug binding to serum albumin: Lessons from biophysical and structural studies. Coordination Chemistry Reviews, 2023, 480, 215026.	18.8	5
628	Molecular Docking, Drug-Likeness Analysis, In Silico Pharmacokinetics, and Toxicity Studies of p-Nitrophenyl Hydrazones as Anti-inflammatory Compounds against COX-2, 5-LOX, and H+/K+ ATPase. Pharmaceutical Fronts, 2022, 04, e250-e266.	0.8	5
629	IN SILICO STUDY OF CHEMICAL COMPOUNDS FROM ARECA NUT (ARECA CATECHU L.) ON GABAA RECEPTOR AS ANTI-INSOMNIA CANDIDATES. International Journal of Applied Pharmaceutics, 0, , 89-95.	0.3	0
630	Regulating the Membrane Affinity of Multi-module Probes to Address the Trade-off between Anchoring and Internalization. Analytical Chemistry, 2023, 95, 2513-2522.	6.5	2
631	Developmental changes in the extent of drug binding to rat plasma proteins. Scientific Reports, 2023, 13, .	3.3	3
632	Adaptation to the intracellular environment of primary human macrophages influences drug susceptibility of Mycobacterium tuberculosis. Tuberculosis, 2023, 139, 102318.	1.9	1
634	Discovery of Small Molecule PARKIN Activator from Antipsychotic/Anti-neuropsychiatric Drugs as Therapeutics for PD: an In Silico Repurposing Approach. Applied Biochemistry and Biotechnology, 2023, 195, 5980-6002.	2.9	4
635	Behind the Curtain: Therapeutic Drug Monitoring of Psychotropic Drugs from a Laboratory Analytical Perspective. Therapeutic Drug Monitoring, 2024, 46, 143-154.	2.0	6
636	Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19. European Journal of Pharmaceutical Sciences, 2023, 184, 106418.	4.0	1
637	Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 <i>in vitro</i> and <i>in vivo</i> . Journal of Antimicrobial Chemotherapy, 2023, 78, 946-952.	3.0	14
638	What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?. Cells, 2023, 12, 709.	4.1	2
639	Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction. Chemistry and Biodiversity, 0, , .	2.1	0
640	Drug discovery processes: When and where the rubber meets the road. , 2023, , 339-415.		1
641	Importance of relative binding of bisphenol A and bisphenol S to plasma proteins for predicting their in vivo potencies. Toxicology and Applied Pharmacology, 2023, 466, 116477.	2.8	0
642	Cannabinoids as Potential Cancer Therapeutics: The Concentration Conundrum. Cannabis and Cannabinoid Research, 0, , .	2.9	1
643	Development of a Novel Tool to Demystify Drug Distribution at Tissueâ€Blood Barriers. ChemBioChem, 0, , .	2.6	0
645	Plasma protein-mediated uptake and contradictions to the free drug hypothesis: a critical review. Drug Metabolism Reviews, 2023, 55, 205-238.	3.6	4

\sim		<u> </u>	
			ЪΤ
\sim	ITAL	KLPU	IN I

#	ARTICLE	IF	CITATIONS
646	Effects of Mouse Kidney Parvovirus on Pharmacokinetics of Chemotherapeutics and the Adenine Model of Chronic Kidney Disease. Comparative Medicine, 2023, , .	1.0	0
647	Discovery of Potential Phytochemicals from Carica papaya Targeting BRCA-1 in Breast Cancer Treatment. Applied Biochemistry and Biotechnology, 2023, 195, 7159-7175.	2.9	3
648	Nitrosamine Impurities: Assessing Concerns through Case Studies. Asian Journal of Chemistry, 2023, 35, 794-804.	0.3	0
649	HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies. Journal of Medicinal Chemistry, 2023, 66, 5907-5936.	6.4	2
650	Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors. Viruses, 2023, 15, 1001.	3.3	1
651	The difference in the cellular uptake of tocopherol and tocotrienol is influenced by their affinities to albumin. Scientific Reports, 2023, 13, .	3.3	2
652	Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDAâ€∎pproved targeted small molecule oncology drugs. Clinical and Translational Science, 2023, 16, 1359-1368.	3.1	0
653	Lead Optimisation: What You Should Know!. , 2023, , 720-768.		0
654	ADME Optimization in Drug Discovery. , 2023, , 298-323.		0
655	Target Discovery Using Deep Learning-Based Molecular Docking and Predicted Protein Structures With AlphaFold for Novel Antipsychotics. Psychiatry Investigation, 2023, 20, 504-514.	1.6	1
656	Modeling ADMET properties based on biomimetic chromatographic data. , 2023, , 573-607.		1
657	Decoding the genetic relationship between Alzheimer's disease and type 2 diabetes: potential risk variants and future direction for North Africa. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
658	Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents. Molecules, 2023, 28, 4628.	3.8	0
659	Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction. Cardiovascular Research, 2023, 119, 1915-1927.	3.8	6
660	Human serum albumin subdomain IB is physiologically adapted for payloading homopterocarpin to human aldehyde dehydrogenase: Combinatorial <i>in vitro</i> and <i>in silico</i> approaches. Journal of Molecular Recognition, 2023, 36, .	2.1	0
661	Clinical Translation of Targeted Protein Degraders. Clinical Pharmacology and Therapeutics, 2023, 114, 558-568.	4.7	7
662	Probing the potential toxicity of trimetazidine by characterizing its interaction with human serum albumin. Methods and Applications in Fluorescence, 2023, 11, 045003.	2.3	0
663	Small volume rapid equilibrium dialysis (RED) measures effects of interstitial parameters on the protein-bound fraction of topical drugs. Journal of Pharmaceutical and Biomedical Analysis, 2023, 234, 115571.	2.8	1

#	Article	IF	CITATIONS
664	Pharmacodynamics of Phytocompound from Dimocarpus Longan Against Breast Cancer Biomarkers. , 2023, , .		0
665	Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants. Journal of Medicinal Chemistry, 0, , .	6.4	1
666	Pharmacokinetics of cefpirome following intravenous and intramuscular administrations in healthy and febrile sheep (Ovis aries). Indian Journal of Animal Sciences, 2023, 93, .	0.2	0
668	Polymers in drug delivery and targeting. , 2023, , 595-634.		0
670	Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation. Cancer Discovery, 2023, 13, 2150-2165.	9.4	2
671	Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science. Cancer Discovery, 2023, 13, 2131-2149.	9.4	1
672	Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting <i>Mycobacterium tuberculosis</i> . ACS Infectious Diseases, 0, , .	3.8	0
673	Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	0
674	CNS distribution of panobinostat in preclinical models to guide dosing for pediatric brain tumors . Journal of Pharmacology and Experimental Therapeutics, 0, , JPET-AR-2023-001826.	2.5	0
675	Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing. Cell Reports Medicine, 2023, 4, 101227.	6.5	0
676	Using CADD tools to inhibit the overexpressed genes FAP, FN1, and MMP1 by repurposing ginsenoside C and Rg1 as a treatment for oral cancer. Frontiers in Molecular Biosciences, 0, 10, .	3.5	0
677	Biopolymers as promising vehicles for drug delivery to the brain. Drug Metabolism Reviews, 2024, 56, 46-61.	3.6	0
678	Tailored Zwitterionic Hemicyanine Reporters for Early Diagnosis and Prognostic Assessment of Acute Renal Failure. Angewandte Chemie - International Edition, 2023, 62, .	13.8	2
679	Tailored Zwitterionic Hemicyanine Reporters for Early Diagnosis and Prognostic Assessment of Acute Renal Failure. Angewandte Chemie, 2023, 135, .	2.0	0
680	Naphthyl-Substituted Indole and Pyrrole Carboxylic Acids as Effective Antibiotic Potentiators—Inhibitors of Bacterial Cystathionine γ-Lyase. International Journal of Molecular Sciences, 2023, 24, 16331.	4.1	2
681	Through a computer monitor darkly: artificial intelligence in absorption, distribution, metabolism and excretion science Xenobiotica, 0, , 1-15.	1.1	0
682	Antitumor Effects of Curcumin on Cervical Cancer with the Focus on Molecular Mechanisms: An Exegesis. Current Pharmaceutical Design, 2023, 29, 3385-3399.	1.9	1
683	Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone. Molecular Psychiatry, 0, , .	7.9	0

#	Article	IF	CITATIONS
684	Comparative Study of Dermal Pharmacokinetics Between Topical Drugs Using Open Flow Microperfusion in a Pig Model. Pharmaceutical Research, 2024, 41, 223-234.	3.5	0
685	Blood–brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics. Expert Opinion on Drug Delivery, 2024, 21, 71-89.	5.0	0
686	Comparison of Tumor Binding Across Tumor Types and Cell Lines to Support Free Drug Considerations for Oncology Drug Discovery. Journal of Pharmaceutical Sciences, 2024, 113, 826-835.	3.3	0
687	J24335 exerts neuroprotective effects against 6-hydroxydopamine-induced lesions in PC12 cells and mice. European Journal of Pharmaceutical Sciences, 2024, 194, 106696.	4.0	0
688	Accurate prediction of Kp,uu,brain based on experimental measurement of Kp,brain and computed physicochemical properties of candidate compounds in CNS drug discovery. Heliyon, 2024, 10, e24304.	3.2	1
689	Human Serum Albumin Immobilized On Magnetizable Beads: A Rapid Method for Compound HSA Binding Study. Journal of Pharmaceutical Sciences, 2024, 113, 1359-1367.	3.3	0
690	Overview of ADME Science. , 2024, , 49-82.		0
691	ADMET-PrInt: Evaluation of ADMET Properties: Prediction and Interpretation. Journal of Chemical Information and Modeling, 2024, 64, 1425-1432.	5.4	0
692	Interspecies variability in protein binding of antibiotics basis for translational PK/PD studies—a case study using cefazolin. Antimicrobial Agents and Chemotherapy, 2024, 68, .	3.2	0
693	Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities. Expert Opinion on Drug Discovery, 2024, 19, 493-506.	5.0	0
694	Discovery of Conformationally Constrained ALK2 Inhibitors. Journal of Medicinal Chemistry, 2024, 67, 4707-4725.	6.4	0